Clarivate PLC 8-K, filed Nov 2, 2020
Clarivate PLC (CLVT)
8-K
2020-11-02
For: 2020-10-30
View Original
Added on
April 11, 2026
About this 8-K
Clarivate PLC filed this 8-K on November 2, 2020, reporting on events of October 30, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
November 2, 2020 (October 30, 2020 )
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization)
N/A | |||||||||||
(Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||
160 Blackfriars Road | |||||||||||
(Address of Principal Executive Offices) | |||||||||||
(44 ) 207-433-4000
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b)
On November 2, 2020, Clarivate Plc issued a press release announcing that Michael S. Klein, a member of the board of directors, had informed the company of his decision to step down from the board. Mr. Klein’s resignation was effective on October 30, 2020. A copy of the press release dated November 2, 2020 is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover page of this Current Report on Form 8-K formatted in Inline XBRL. | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CLARIVATE PLC | ||||||||
| Date: November 2, 2020 | By: | /s/ Richard Hanks | ||||||
| Name: | Richard Hanks | |||||||
| Title: | Chief Financial Officer | |||||||
Clarivate Announces Change to its Board of Directors
London, U.K., November 2, 2020 – (PR Newswire) - Clarivate Plc (NYSE: CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Michael S. Klein, a member of the board of directors, has informed the Company of his decision to step down from the board. Mr. Klein previously served as Chairman of Churchill Capital Corp, a special purpose acquisition company (SPAC), which merged with Clarivate in May 2019.
Jerre Stead, Executive Chairman and CEO said: “On behalf of the entire company and the Board of Directors, I am very grateful for Michael’s contributions and guidance over the past couple years. Clarivate has benefited significantly from Michael’s business and leadership expertise. We wish him well with his future endeavors.”
With Mr. Klein’s departure, the Clarivate Board will consist of 12 members.
About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions. Covering scientific and academic research, pharmaceutical, biotech and healthcare intelligence and intellectual property services, we help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.
Category: Board of Director change
Source: Clarivate Plc
Investor Relations Contact
Mark Donohue, Head of Investor Relations
mark.donohue@clarivate.com
+1 (215) 243 2202
Media Contact
Tabita Seagrave, Head of Global Corporate Communications
media.enquiries@clarivate.com
1